Federal Pre-Emption in Medical Device and Pharmaceutical Litigation


Over the past two years, the United States Supreme Court has had two opportunities to address and add to the jurisprudence in the area of federal pre-emption of state law claims regarding allegedly defective medical devices and prescription drugs, which are both regulated by the US Food and Drug Administration (FDA). In Riegel v. Medtronic, Inc., 128 S.Ct. 999 (U.S. 2008), the United States Supreme Court held that the Medical Device Act's pre-emption clause expressly pre-empts state law claims challenging the safety and effectiveness of a medical device marketed in a form that received premarket approval from the FDA. The Court made it explicitly clear, however, that such claims are only pre-empted insofar as they seek to impose state requirements that are "different from, or in addition to" the requirements imposed by federal law. Id. at 1011.

Please see full article below for more information.

LOADING PDF: If there are any problems, click here to download the file.

Published In: Administrative Agency Updates, Conflict of Laws Updates, Health Updates, Products Liability Updates

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Dinsmore & Shohl LLP | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »